GSK: UBS lowers EPS forecast by 5%.

(CercleFinance.com) - UBS announces that it has reduced its EPS estimate by about 5%, ahead of expected weakness in Q3.
The analyst confirms a Neutral rating on the stock, with an unchanged TP of 1,580 pence.

The 5% EPS reduction reflects recent weakness in US vaccine sales. Chinese Shingrix is also weak. No change in target price as the Zantac litigation has been resolved, UBS says.

For 2024, the laboratory expects sales to rise by around +7% to +9% (vs. +5% to +7% previously), with core EBIT expected between +11% and +13% (vs. +9% to +11% previously) and core EPS up by +10% to +12% (vs. +8% to +10% previously).


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.